GlassScriptPhysician profile
Stephanie Ford
NPI 1811969744
$10,095.04
in general payments reported to CMS, 2019-2025
17 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,008 · 2022: $1,869 · 2023: $2,156 · 2024: $2,577 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,114 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,113.75 |
| Education | $104.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,687.84 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $1,622.44 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,233.75 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $976.83 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $724.53 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $343.72 | 2021-2023 | Invega Sustenna, Invega Trinza, Invega |
| Abbvie INC. | $290.86 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $269.41 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $251.32 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $245.15 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $169.96 | 2021-2022 | |
| Indivior INC. | $121.69 | 2022-2023 | Perseris |
| Almatica Pharma LLC | $50.68 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $48.57 | 2022 | |
| Luye Pharma (USA) LTD. | $33.88 | 2025 | Erzofri Extended-Release |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $13.32 | 2022 | |
| Janssen Biotech, INC. | $11.09 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.